Nice. More significant than the AML ann for me.
These patients are struggling for options, and ptx200 seems to be doing what's on the box, even though the right dosing has not been found yet. I can imagine pharma's being interested in having a closer look.
Next the biggie, phase 2 in breast cancer, fully dosed, also with a difficult to treat bunch.
Good breast cancer data will also add interest in ptx200 as a treatment for other cancers too.
"you went and saved the best for last...."
Ann: Encouraging data from PTX-200 ovarian cancer trial, page-23
-
- There are more pages in this discussion • 149 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
